Latest Deals
The acquisition will include Aliada’s ALIA-1758, which is in development for Alzheimer’s disease. Credit: rt_Photo / Shutterstock
AbbVie signs agreement to acquire Aliada for $1.4bn
AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The deal will include Aliada’s lead investigational product, ALIA-1758, which is in development for Alzheimer’s disease. Aliada is at the forefront of advancing therapies with a blood-brain barrier (BBB)-crossing technology that targets transferrin and CD98 receptors, which are abundant in brain endothelial cells.
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA). The collaboration will focus on Novo Nordisk’s obesity and type 2 diabetes products, chief among them a once-monthly GLP-1RA to be developed as the joint venture’s lead candidate.
Metsera raises $215m in Series B round for weight loss candidates
Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio. The funding, via a Series B raise, was led by Wellington Management and Venrock Healthcare Capital Partners and joined by new investors including Fidelity Management & Research Company, and Janus Henderson Investors.
ALK snags EU and Canada rights to nasal spray Neffy for $145m
ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, among other countries, from ARS Pharmaceuticals for $145m. ARS will retain the rights for the treatment for anaphylaxis in the US, Australia, New Zealand, Japan and China, while Danish allergy immunotherapy specialist ALK will take on remaining global rights, as per a 9 November press release.
